Although Alzheimer’s disease (AD) was described over a century ago, there are no effective approaches to its prevention and treatment. Such a slow progress is explained, at least in part, by our incomplete understanding of the mechanisms underlying the pathogenesis of AD. Here, I champion a hypothesis whereby AD is initiated on a disruption of the blood-brain barrier (BBB) caused by either genetic or non-genetic risk factors. The BBB disruption leads to an autoimmune response against pyramidal neurons located in the allo- and neocortical structures involved in memory formation and storage. The response caused by the adaptive immune system is not strong enough to directly kill neurons but may be sufficient to make them selectively vulnerable to neurofibrillary pathology. This hypothesis is based on the recent data showing that memory formation is associated with epigenetic chromatin modifications and, therefore, may be accompanied by expression of memory-specific proteins recognized by the immune system as “non-self” antigens. The autoimmune hypothesis is testable, and I discuss potential ways for its experimental and clinical verification. If confirmed, this hypothesis can radically change therapeutic approaches to AD prevention and treatment.
AbdullahiWTripathiDRonaldsonPT. 2018. Blood-brain barrier dysfunction in ischemic stroke: targeting tight junctions and transporters for vascular protection. Am J Physiol Cell Physiol315(3):C343–56.
2.
AbrahamWCJonesODGlanzmanDL. 2019. Is plasticity of synapses the mechanism of long-term memory storage?NPJ Sci Learn4:9.
3.
AkinyemiROMukaetova-LadinskaEBAttemsJIharaMKalariaRN. 2013. Vascular risk factors and neurodegeneration in ageing related dementias: Alzheimer’s disease and vascular dementia. Curr Alzheimer Res10(6):642–53.
4.
AkiyamaHBargerSBarnumSBradtBBauerJColeGM. 2000. Inflammation and Alzheimer’s disease. Neurobiol Aging21(3):383–421.
5.
AlarcónGMartinezJKeraiSVLacruzMEQuirogaRQSelwayRP, and others. 2012. In vivo neuronal firing patterns during human epileptiform discharges replicated by electrical stimulation. Clin Neurophysiol123(9):1736–44.
6.
AlmoldaBGonzalezBCastellanoB.2011. Antigen presentation in EAE: role of microglia, macrophages and dendritic cells. Front Biosci16:1157–71.
7.
ArriagadaPVGrowdonJHHedley-WhyteETHymanBT. 1992. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology42(3pt 1):631–9.
8.
ArshavskyYI. 2006a. Alzheimer’s disease, brain immune privilege and memory: a hypothesis. J Neural Transm (Vienna) 113(11):1697–707.
9.
ArshavskyYI. 2006b. “The seven sins” of the Hebbian synapse: can the hypothesis of synaptic plasticity explain long-term memory consolidation? Prog Neurobiol80(3):99–113.
10.
ArshavskyYI. 2010. Why Alzheimer’s disease starts with a memory impairment: neurophysiological insight. J Alzheimer’s Dis20(1):5–16.
11.
ArshavskyYI. 2014. Alzheimer disease and cellular mechanisms of memory storage. J Neuropathol Exp Neurol73(3):192–205.
12.
ArshavskyYI. 2017. Neurons versus networks: the interplay between individual neurons and neural networks in cognitive functions. Neuroscientist23(4):341–55.
BanksWA. 2015. The blood-brain barrier in neuroimmunology: tales of separation and assimilation. Brain Behav Immun44(1):1–8.
15.
BarageSHSonawaneKD. 2015. Amyloid cascade hypothesis: pathogenesis and therapeutic strategies in Alzheimer’s disease. Neuropeptides52(1):1–18.
16.
BayraktarGKreutzMR. 2018. Neuronal DNA methyltransferases: epigenetic mediators between synaptic activity and gene expression? Neuroscientist24(2):171–85.
17.
BejaninASchonhautDRLa JoieRKramerJHBakerSLSosaN, and others. 2017. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer’s disease. Brain140(12):3286–300.
18.
BenarrochEE. 2018. Locus coeruleus. Cell Tissue Res373(1):221–32.
19.
BiancardiVCSternJE. 2016. Compromised blood-brain barrier permeability: novel mechanism by which circulating angiotensin II signals to sympathoexcitatory centres during hypertension. J Physiol594(6):1591–600.
20.
BirdA. 2002. DNA methylation patterns and epigenetic memory. Genes Dev16(1):6–21.
21.
BironKEDicksteinDLGopaulRJefferiesWA. 2011. Amyloid triggers extensive cerebral angiogenesis causing blood brain barrier permeability and hypervascularity in Alzheimer’s disease. PLoS One6(8):e23789.
22.
BogushMHeldtNAPersidskyY.2017. Blood brain barrier injury in diabetes: unrecognized effects on brain and cognition. J Neuroimmune Pharmacol12(4):593–601.
23.
BolandMJNazorKLLoringJF. 2014. Epigenetic regulation of pluripotency and differentiation. Circ Res115(2):311–24.
24.
BoonenRAvan TijnPZivkovicD.2009. Wnt signaling in Alzheimer’s disease: up or down, that is the question. Ageing Res Rev8(1):71–82.
25.
BourasCRiedererBMHofPRGiannakopoulosP.2003. Induction of MC-1 immunoreactivity in axons after injection of the Fc fragment of human immunoglobulins in macaque monkeys. Acta Neuropathol105(1):58–64.
26.
BourasCRiedererBMKövariEHofPRGiannakopoulosP.2005. Humoral immunity in brain aging and Alzheimer’s disease. Brain Res Rev48(3):477–87.
27.
BraakHAlafuzoffIArzbergerTKretzschmarHDel TrediciK.2006. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol112(4):389–404.
28.
BraakHBraakE.1991. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol82(4):239–59.
29.
BraakHDel TrediciK.2011a. The pathological process underlying Alzheimer’s disease in individuals under thirty. Acta Neuropathol121(2):171–81.
30.
BraakHDel TrediciK.2011b. Alzheimer’s pathogenesis: is there neuron-to-neuron propagation? Acta Neuropathol121(5):589–95.
31.
BraakHDel TrediciK.2015. Neuroanatomy and Pathology of Sporadic Alzheimer’s Disease. Cham, Switzerland: Springer.
32.
BraakHDel TrediciK.2018. Spreading of tau pathology in sporadic Alzheimer’s disease along cortico-cortical top-down connections. Cereb Cortex28(9):3372–84.
33.
BraakHDel TrediciKSchultzCBraakE.2000. Vulnerability of select neuronal types to Alzheimer’s disease. Ann NY Acad Sci924:53–61.
34.
BrookEMamoJWongRAl-SalamiHFalascaMLamV, and others. 2019. Blood-brain barrier disturbances in diabetes-associated dementia: therapeutic potential for cannabinoids. Pharmacol Res141:291–7.
35.
BynoeMSViretCYanAKimDG. 2015. Adenosine receptor signaling: a key to opening the blood-brain door. Fluids Barriers CNS12:20.
36.
CayrolRWosikKBerardJLDodelet-DevillersAIferganIKebirH, and others. 2008. Activated leukocyte cell adhesion molecule promotes leukocyte trafficking into the central nervous system. Nat Immunol9(2):137–45.
37.
ChalmersKWilcockGKLoveS.2003. APOEɛ4 influences the pathological phenotype of Alzheimer’s disease by favouring cerebrovascular over parenchymal accumulation of Aβ protein. Neuropathol Appl Neurobiol29(3):231–8.
38.
ChatterjeeSMudherA.2018. Alzheimer’s disease and type 2 diabetes: a critical assessment of the shared pathological traits. Front Neurosci12:383.
39.
CostanzaAWeberKGandySBourasCHofPRGiannakopoulosP, and others. 2011. Contact sport-related chronic traumatic encephalopathy in the elderly: clinical expression and structural substrates. Neuropathol Appl Neurobiol37(6):570–84.
40.
CrickF. 1984. Memory and molecular turnover. Nature312(5990):101.
41.
D’AndreaMR. 2003. Evidence linking neuronal cell death to autoimmunity in Alzheimer’s disease. Brain Res982(1):19–30.
42.
DargahiNKatsaraMTseliosTAndroutsouMEde CourtenMMatsoukasJ, and others. 2017. Multiple sclerosis: immunopathology and treatment update. Brain Sci7(7). pii: E78.
43.
DavisHPSquireLR. 1984. Protein synthesis and memory: a review. Psychol Bull96(3):518–59.
44.
DicksteinDLWalshJBrautigamHStocktonSDGandySHofPR. 2010. Role of vascular risk factors and vascular dysfunction in Alzheimer’s disease. Mt Sinai J Med77(1):82–102.
45.
DoshiAChatawayJ.2017. Multiple sclerosis, a treatable disease. Clin Med (Lond)17(6):530–6.
46.
DuboisBAlbertML. 2004. Amnestic MCI or prodromal AD?Lancet Neurol3(4):246–8.
47.
EhrenbergAJNguyAKTheofilasPDunlopSSuemotoCKDi LorenzoAT, and others. 2017. Quantifying the accretion of hyperphosphorylated tau in the locus coeruleus and dorsal raphe nucleus: the pathological building blocks of early Alzheimer’s disease. Neuropathol Appl Neurobiol43(5):393–408.
48.
ElobeidASoininenHAlafuzoffI.2012. Hyperphosphorylated tau in young and middle-aged subjects. Acta Neuropathol123(1):97–104.
49.
EngelhardtBLiebnerS.2014. Novel insights into the development and maintenance of the blood-brain barrier. Cell Tissue Res355(3):687–99.
50.
EngelhardtBRansohoffRM. 2012. Capture, crawl, cross: the T cell code to breach the blood-brain barriers. Trends Immunol33(12):579–89.
51.
FalconBZivanovJZhangWMurzinAGGarringerHJVidalR, and others. 2019. Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules. Nature568(7752):420–3.
52.
GallegosDAChanUChenLFWestAE. 2018. Chromatin regulation of neuronal maturation and plasticity. Trends Neurosci41(5):311–24.
53.
GiannakopoulosPHerrmannFRBussièreTBourasCKövariEPerlDP, and others. 2003. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease. Neurology60(9):1495–500.
54.
GoedertMEisenbergDSCrowtherRA. 2017. Propagation of tau aggregates and neurodegeneration. Annu Rev Neurosci40:189–210.
55.
GoldwaserELAcharyaNKSarkarAGodseyGNageleRG. 2016. Breakdown of the cerebrovasculature and blood-brain barrier: a mechanistic link between diabetes mellitus and Alzheimer’s disease. J Alzheimers Dis54(2):445–56.
56.
GötzJBodeaLGGoedertM.2018. Rodent models for Alzheimer disease. Nat Rev Neurosci19(10):583–98.
57.
GrinbergLTRübUFerrettiRENitriniRFarfelJMPolichisoL, and others. 2009. The dorsal raphe nucleus shows phospho-tau neurofibrillary changes before the transentorhinal region in Alzheimer’s disease. A precocious onset?Neuropathol Appl Neurobiol35(4):406–16.
58.
GroberEDicksonDSliwinskiMJBuschkeHKatzMCrystalH, and others. 1999. Memory and mental status correlates of modified Braak staging. Neurobiol Aging20(6):573–9.
59.
GuerrieroFSgarlataCFrancisMMauriziNFaragliAPernaS, and others. 2017. Neuroinflammation, immune system and Alzheimer disease: searching for the missing link. Aging Clin Exp Res29(5):821–31.
60.
GurnikSDevrajKMacasJYamajiMStarkeJScholzA, and others. 2016. Angiopoietin-2-induced blood-brain barrier compromise and increased stroke size are rescued by VE-PTP-dependent restoration of Tie2 signaling. Acta Neuropathol131(5):753–73.
61.
HardyJAHigginsGA. 1992. Alzheimer’s disease: the amyloid cascade hypothesis. Science256(5054):184–5.
62.
HechtMKrämerLMvon ArnimCAFOttoMThalDR. 2018. Capillary cerebral amyloid angiopathy in Alzheimer’s disease: association with allocortical/hippocampal microinfarcts and cognitive decline. Acta Neuropathol135(5):681–94.
63.
HerreMKorbE.2019. The chromatin landscape of neuronal plasticity. Curr Opin Neurobiol59:79-–86.
64.
HollidayR. 1999. Is there an epigenetic component in long-term memory?J Theor Biol200(3):339–41.
65.
HolmesBBDiamondMI. 2014. Prion-like properties of tau protein: the importance of extracellular tau as a therapeutic target. J Biol Chem89(29):19855–61.
66.
HuangYMuckeL.2012. Alzheimer mechanisms and therapeutic strategies. Cell148(6):1204–22.
67.
IqbalKLiuFGongCX. 2016. Tau and neurodegenerative disease: the story so far. Nat Rev Neurol12(1):15–27.
68.
JagustW. 2018. Imaging the evolution and pathophysiology of Alzheimer disease. Nat Rev Neurosci19(11):687–700.
69.
JellingerKA. 2004. Head injury and dementia. Curr Opin Neurol17(6):719–23.
70.
JellingerKABancherC.1997. Proposals for re-evaluation of current autopsy criteria for the diagnosis of Alzheimer’s disease. Neurobiol Aging18(4 suppl):S55–65.
71.
JiangXAndjelkovicAVZhuLYangTBennettMVLChenJ, and others. 2018. Blood-brain barrier dysfunction and recovery after ischemic stroke. Prog Neurobiol163:144–71.
72.
KalariaRN. 1999. The blood-brain barrier and cerebrovascular pathology in Alzheimer’s disease. Ann N Y Acad Sci893:113–25.
73.
KametaniFHasegawaM.2018. Reconsideration of amyloid hypothesis and tau hypothesis in Alzheimer’s disease. Front Neurosci12:25.
74.
KassnerAMeraliZ.2015. Assessment of blood-brain barrier disruption in stroke. Stroke46(11):3310–5.
75.
KeepRFZhouNXiangJAndjelkovicAVHuaYXiG.2014. Vascular disruption and blood-brain barrier dysfunction in intracerebral hemorrhage. Fluids Barriers CNS11:18.
76.
KennedyAJSweattJD. 2016. Drugging the methylome: DNA methylation and memory. Crit Rev Biochem Mol Biol51(3):185–94.
77.
KnopmanDS2019. Lowering of amyloid-β by β-secretase inhibitors—some informative failures. N Engl J Med380(15):1476–8.
78.
KumarMCohenDEisdorferC.1988. Serum IgG brain reactive antibodies in Alzheimer disease and Down syndrome. Alzheimer Dis Assoc Disord2(1):50–5.
79.
Kumar-SinghSPiriciDMcGowanESerneelsSCeuterickCHardyJ, and others. 2005. Dense-core plaques in Tg2576 and PSAPP mouse models of Alzheimer’s disease are centered on vessel walls. Am J Pathol167(2):527–43.
80.
LevensonJMSweattJD. 2005. Epigenetic mechanisms in memory formation. Nat Rev Neurosci6(1):108–18.
81.
LaFerlaFMGreenKN. 2012. Animal models of Alzheimer disease. Cold Spring Harb Perspect Med2(11):a006320.
82.
LiebnerSDijkhuizenRMReissYPlateKHAgalliuDConstantin.G2018. Functional morphology of the blood-brain barrier in health and disease. Acta Neuropathol135(3):311–36.
83.
LiuYDongYHLyuPYChenWHLiR.2018. Hypertension-induced cerebral small vessel disease leading to cognitive impairment. Chin Med J (Engl)131(5):615–9.
84.
LiuLWanWXiaSKalionisBLiY.2014. Dysfunctional Wnt/β-catenin signaling contributes to blood-brain barrier breakdown in Alzheimer’s disease. Neurochem Int75:19–25.
85.
LoweVJWisteHJSenjemMLWeigandSDTherneauTMBoeveBF, and others. 2018. Widespread brain tau and its association with ageing, Braak stage and Alzheimer’s dementia. Brain141(1):271–87.
86.
MagakiSTangZTungSWilliamsCKLoDYongWH, and others. 2018. The effects of cerebral amyloid angiopathy on integrity of the blood-brain barrier. Neurobiol Aging70(1):70–7.
MayeuxROttmanRMaestreGNgaiCTangMXGinsbergH, and others. 1995. Synergistic effects of traumatic head injury and apolipoprotein-epsilon 4 in patients with Alzheimer’s disease. Neurology45(3):555–7.
89.
MansvelderHDVerhoogMBGoriounovaNA. 2019. Synaptic plasticity in human cortical circuits: cellular mechanisms of learning and memory in the human brain? Curr Opin Neurobiol54:186–93.
90.
McGeerPLAkiyamaHItagakiSMcGeerEG. 1989. Immune system response in Alzheimer’s disease. Can J Neurol Sci16(4 suppl):516–27.
91.
McGowanPOSzyfM.2010. Environmental epigenomics: understanding the effects of parental care on the epigenome. Essays Biochem48(1):275–87.
92.
McKeeACSteinTDKiernanPTAlvarezVE. 2015. The neuropathology of chronic traumatic encephalopathy. Brain Pathol25(3):350–64.
93.
MerliniMKirabaliTKulicLNitschRMFerrettiMT. 2018. Extravascular CD3+ T cells in brains of Alzheimer disease patients correlate with tau but not with amyloid pathology: an immunohistochemical study. Neurodegener Dis18(1):49–56.
94.
MongilloGRumpelSLoewensteinY.2017. Intrinsic volatility of synaptic connections—a challenge to the synaptic trace theory of memory. Curr Opin Neurobiol46:7–13.
95.
MontagneAZhaoZZlokovicBV. 2017. Alzheimer’s disease: a matter of blood-brain barrier dysfunction? J Exp Med214(11):3151–69.
96.
MontenigroPHBaughCMDaneshvarDHMezJBudsonAEAuR, and others. 2014. Clinical subtypes of chronic traumatic encephalopathy: literature review and proposed research diagnostic criteria for traumatic encephalopathy syndrome. Alzheimers Res Ther6(5):68.
97.
MorrisonJHHofPR. 2002. Selective vulnerability of corticocortical and hippocampal circuits in aging and Alzheimer’s disease. Prog Brain Res136:467–86.
98.
MrdjenDFoxEJBukhariSAMontineKSBendallSCMontineTJ. 2019. The basis of cellular and regional vulnerability in Alzheimer’s disease. Acta Neuropathol138(5):729–49.
99.
MudherAColinMDujardinSMedinaMDewachterIAlavi NainiSM, and others. 2017. What is the evidence that tau pathology spreads through prion-like propagation?Acta Neuropathol Commun5(1):99.
100.
NagyCTureckiG.2012. Sensitive periods in epigenetics: bringing us closer to complex behavioral phenotypes. Epigenomics4(4):445–57.
101.
NationDASweeneyMDMontagneASagareAPD’OrazioLMPachicanoM, and others. 2019. Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat Med25(2):270–6.
102.
NelsonPTAlafuzoffIBigioEHBourasCBraakHCairnsNJ, and others. 2012. Correlation of Alzheimer’s disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol71(5):362–81.
103.
NevesGCookeSFBlissTV. 2008. Synaptic plasticity, memory and the hippocampus: a neural network approach to causality. Nat Rev Neurosci9(1):65–75.
104.
NewcombeEACamats-PernaJSilvaMLValmasNHuatTJMedeirosR.2018. Inflammation: the link between comorbidities, genetics, and Alzheimer’s disease. J Neuroinflammation15(1):276.
105.
NicollJARobertsGWGrahamDI. 1996. Amyloid β-protein, APOE genotype and head injury. Ann N Y Acad Sci777:271–5.
106.
OhmTGMüllerHBraakHBohlJ.1995. Close-meshed prevalence rates of different stages as a tool to uncover the rate of Alzheimer’s disease-related neurofibrillary changes. Neuroscience64(1):209–17.
107.
O’NealMAStallingsNRMalterJS. 2018. Alzheimer’s disease, dendritic spines, and calcineurin inhibitors: a new approach? ACS Chem Neurosci9(6):1233–34.
108.
PachterJSde VriesHEFabryZ.2003. The blood-brain barrier and its role in immune privilege in the central nervous system. J Neuropathol Exp Neurol62(6):593–604.
109.
PanzaFLozuponeMSeripaDImbimboBP. 2019. A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease. Nat Rev Neurol15(1):73–88.
110.
ParkerESCahillLMcGaughJL2006. A case of unusual autobiographical remembering. Neurocase12(1):35–49.
111.
Peña de OrtizSArshavskyYI. 2001. DNA recombination as a possible mechanism in declarative memory: a hypothesis. J Neurosci Res63(1):72–81.
112.
PenninkilampiRBrothersHMEslickGD. 2017. Safety and efficacy of anti-amyloid-β-immunotherapy in Alzheimer’s disease: a systematic review and meta-analysis. J Neuroimmune Pharmacol12(2):194–203.
113.
PolancoJCLiCBodeaLGMartinez-MarmolRMeunierFAGötzJ.2018. Amyloid-β and tau complexity—towards improved biomarkers and targeted therapies. Nat Rev Neurol14(1):22–39.
114.
PremkumarDRCohenDLHederaPFriedlandRPKalariaRN. 1996. Apolipoprotein E-epsilon4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer’s disease. Am J Pathol148(6):2083–95.
115.
QueenanBNRyanTJGazzanigaMSGallistelCR. 2017. On the research of time past: the hunt for the substrate of memory. Ann N Y Acad Sci1396:108–25.
116.
Quian QuirogaR. 2012. Concept cells: the building blocks of declarative memory functions. Nat Rev Neurosci13(8):587–97.
117.
Quian QuirogaRKraskovAKochCFriedI. 2009. Explicit encoding of multimodal percepts by single neurons in the human brain. Curr Biol19(15):1308–13.
118.
Ramos-CejudoJWisniewskiTMarmarCZetterbergHBlennowKde LeonMJ, and others. 2018. Traumatic brain injury and Alzheimer’s disease: the cerebrovascular link. EBioMedicine28:21–30.
119.
RapoportSI. 2001. Advances in osmotic opening of the blood-brain barrier to enhance CNS chemotherapy. Expert Opin Investig Drugs10(10):1809–18.
120.
RapoportSINelsonPT. 2011. Biomarkers and evolution in Alzheimer disease. Prog Neurobiol95(4):510–3.
121.
RichardsonAGalvanVLinALOddoS.2015. How longevity research can lead to therapies for Alzheimer’s disease: the rapamycin story. Exp Gerontol68:51–8.
122.
RogersJLuber-NarodJStyrenSDCivinWH. 1988. Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer’s disease. Neurobiol Aging9(4):339–49.
123.
RommerPSMiloRHanMHSatyanarayanSSellnerJHauerL, and others. 2019. Immunological aspects of approved MS therapeutics. Front Immunol10:1564.
124.
Rovelet-LecruxAHannequinDRauxGLe MeurNLaquerrièreAVitalA, and others. 2006. APP locus duplication causes autosomal dominant early-onset alzheimer disease with cerebral amyloid angiopathy. Nat Genet38(1):24–6.
SardiFFassinaLVenturiniLInguscioMGuerrieroFRolfoE, and others. 2011. Alzheimer’s disease, autoimmunity and inflammation. The good, the bad and the ugly. Autoimmun Rev11(2):149–53.
128.
ScheltensPBlennowKBretelerMMde StrooperBFrisoniGBSallowayS, and others. 2016. Alzheimer’s disease. Lancet388(10043):505–17.
129.
SelkoeDJHardyJ.2016. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med8(6):595–608.
130.
SiegenthalerJASohetFDanemanR.2013. ‘Sealing off the CNS’: cellular and molecular regulation of blood-brain barrier genesis. Curr Opin Neurobiol23(6):1057–64.
131.
SiegmundKDConnorCMCampanMLongTIWeisenbergerDJBiniszkiewiczD, and others. 2007. DNA methylation in the human cerebral cortex is dynamically regulated throughout the life span and involves differentiated neurons. PLoS One2(9):e895.
132.
SinghVK. 1997. Neuroautoimmunity: pathogenic implications for Alzheimer’s disease. Gerontology 43(1–2):79–94.
133.
SmithAD. 2002. Imaging the progression of Alzheimer pathology through the brain. Proc Natl Acad Sci U S A99(7):4135–7.
134.
SmithZDMeissnerA.2013. DNA methylation: roles in mammalian development. Nat Rev Genet14(3):204–20.
135.
SquireLRKandelER. 2003. Memory: From Mind to Molecules. New York, NY: Scientific Amer Library.
136.
SudduthTLWeekmanEMBrothersHMBraunKWilcockDM. 2014. β-amyloid deposition is shifted to the vasculature and memory impairment is exacerbated when hyperhomocysteinemia is induced in APP/PS1 transgenic mice. Alzheimers Res Ther6(3):32.
137.
SweeneyMDSagareAPZlokovicBV. 2018. Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol14(3):133–50.
138.
TaglialatelaGRastelliniCCicaleseL.2015. Reduced incidence of dementia in solid organ transplant patients treated with Calcineurin inhibitors. J Alzheimers Dis47(2):329–33.
139.
TaiLMThomasRMarottoliFMKosterKPKanekiyoTMorrisAW, and others. 2016. The role of APOE in cerebrovascular dysfunction. Acta Neuropathol131(5):709–23.
140.
TcwJGoateAM. 2017. Genetics of β-amyloid precursor protein in Alzheimer’s disease. Cold Spring Harb Perspect Med 7(6). pii: a024539.
141.
ThalDRGhebremedhinERübUYamaguchiHDel TrediciKBraakH.2002. Two types of sporadic cerebral amyloid angiopathy. J Neuropathol Exp Neurol61(3):282–93.
142.
ThalDRHolzerMRübUWaldmannGGünzelSZedlickD, and others. 2000. Alzheimer-related tau-pathology in the perforant path target zone and in the hippocampal stratum oriens and radiatum correlates with onset and degree of dementia. Exp Neurol163(1):98–110.
143.
TogoTAkiyamaHIsekiEKondoHIkedaKKatoM, and others. 2002. Occurrence of T cells in the brain of Alzheimer’s disease and other neurological diseases. J Neuroimmunol124(1):83–92.
144.
TonegawaSLiuXRamirezSRedondoR.2015. Memory engram cells have come of age. Neuron87(5):918–31.
145.
TownTTanJFlavellRAMullanM2005. T-cells in Alzheimer’s disease. Neuromolecular Med7(3):255–64.
146.
TreffertDAChristensenDD. 2005. Inside the mind of a savant. Sci Am293(6):108–13.
147.
TrettenbreinPC. 2016. The demise of the synapse as the locus of memory: a looming paradigm shift? Front Syst Neurosci10:88.
148.
UjiieMDicksteinDLCarlowDAJefferiesWA. 2003. Blood-brain barrier permeability precedes senile plaque formation in an Alzheimer disease model. Microcirculation10(6):463–70.
149.
van de HaarHJBurgmansSJansenJFvan OschMJvan BuchemMAMullerM, and others. 2016. Blood-brain barrier leakage in patients with early Alzheimer disease. Radiology281(2):527–35.
150.
van der KantRGoldsteinLSBOssenkoppeleR.2020. Amyloid-β-independent regulators of tau pathology in Alzheimer disease. Nat Rev Neurosci21(1):21–35.
151.
WaismanAJohannL.2018. Antigen-presenting cell diversity for T cell reactivation in central nervous system autoimmunity. J Mol Med (Berl)96(12):1279–92.
152.
WalkerLCJuckerM.2017. The exceptional vulnerability of humans to Alzheimer’s disease. Trends Mol Med23(6):534–45.
153.
WalshDMSelkoeDJ. 2004. Deciphering the molecular basis of memory failure in Alzheimer’s disease. Neuron44(1):181–93.
154.
WangCYuJTMiaoDWuZCTanMSTanL.2014. Targeting the mTOR signaling network for Alzheimer’s disease therapy. Mol Neurobiol49(1):120–35.
155.
WekerleHSunDOropeza-WekerleRLMeyermannR.1987. Immune reactivity in the nervous system: modulation of T-lymphocyte activation by glial cells. J Exp Biol132:43–57.
156.
WisniewskiTBoutajangoutA.2010. Immunotherapeutic approaches for Alzheimer’s disease in transgenic mouse models. Brain Struct Funct214(2):201–18.
157.
YamazakiYKanekiyoT.2017. Blood-brain barrier dysfunction and the pathogenesis of Alzheimer’s disease. Int J Mol Sci18(9):1965.
158.
ZenaroEPiacentinoGConstantinG.2017. The blood-brain barrier in Alzheimer’s disease. Neurobiol Dis107(1):41–56.
159.
ZhouVWGorenABernsteinBE. 2011. Charting histone modifications and the functional organization of mammalian genomes. Nat Rev Genet12(1):7–18.
160.
ZivNEBrennerN2018. Synaptic tenacity or lack thereof: spontaneous remodeling of synapses. Trends Neurosci41(2):89–99.
161.
ZlokovicBV. 2008. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron57(2):178–201.
